Teva Pharmaceutical Industries (BUL:TEV) - Cotización, noticias y análisis

Resumen de acción TEV

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

Acerca de la empresa

TEV fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 60.4% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 64.82%

Análisis de riesgos

Acciones altamente ilíquidas

Competidores de Teva Pharmaceutical Industries Limited

Tchaikapharma High Quality Medicines AD

BUL:THQM

лв1.5b

Sopharma AD

BUL:SFA

лв997.0m

Eisai

TSE:4523

JP¥1.9t

Catalent

NYSE:CTLT

US$10.1b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Teva Pharmaceutical Industries
Historical stock prices
Current Share Price	US$9.38
52 Week High	US$9.84
52 Week Low	US$8.14
Beta	1.19
1 Month Change	0%
3 Month Change	n/a
1 Year Change	11.67%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	13.42%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	TEV	BG Pharmaceuticals	Mercado BG
7D	0%	1.4%	1.3%
1Y	11.7%	10.0%	17.2%

Rentabilidad vs. Industria: TEV superó al sector BG Pharmaceuticals , que obtuvo un rendimiento del 3.4% el año pasado.

Rentabilidad vs. Mercado: TEV igualó al mercado BG, que obtuvo un rendimiento del 17.1% el año pasado.

Volatilidad de los precios

Is TEV's price volatile compared to industry and market?
TEV volatility
TEV Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	3.9%
10% most volatile stocks in BG Market	9.2%
10% least volatile stocks in BG Market	2.4%

Precio estable de las acciones: TEV no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de TEV en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1901	34,565	Richard Francis	www.tevapharm.com

Resumen de fundamentos de Teva Pharmaceutical Industries Limited

¿Cómo se comparan los beneficios e ingresos de Teva Pharmaceutical Industries con su capitalización de mercado?
Estadísticas fundamentales de TEV
Capitalización bursátil	€10.23b
Beneficios(TTM)	-€2.05b
Ingresos (TTM)	€14.19b

0.7x

Ratio precio-ventas (PS)

-5.0x

Ratio precio-beneficio (PE)

¿Está TEV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TEV
Ingresos	US$15.27b
Coste de los ingresos	US$8.27b
Beneficio bruto	US$7.00b
Otros gastos	US$9.21b
Beneficios	-US$2.21b

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.97
Margen bruto	45.84%
Margen de beneficio neto	-14.46%
Ratio deuda/patrimonio	265.9%

¿Cómo se ha desempeñado TEV a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TEV

Recompensas

Análisis de riesgos

Competidores de Teva Pharmaceutical Industries Limited

BUL:THQM

лв1.5b

BUL:SFA

лв997.0m

TSE:4523

JP¥1.9t

NYSE:CTLT

US$10.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Recent updates

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023

Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY

Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023

Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims

Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022

Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression

Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc

Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021)

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer

Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022

Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022

Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S

Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Forecast to breakeven in 2021

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS US$0.19 (vs US$0.13 in 2Q 2020)

Insufficient new directors

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Teva Pharmaceutical Industries Limited

0.7x

-5.0x

Beneficios e Ingresos